Not independent
Tenure on this board
19.3 yrs
1 nominee · 4 ballot items.
Four proposals: (1) elect one director (Howard W. Robin) to serve until 2029; (2) approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase authorized shares by 3,000,000; (3) ratify Ernst & Young LLP as independent registered public accounting firm for fiscal 2026; and (4) approve a non-binding advisory resolution on executive compensation (“say-on-pay”).
To elect one director (Howard W. Robin) to a term expiring at the 2029 Annual Meeting.
To approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares authorized for issuance under the plan by 3,000,000 shares (post 1:15 reverse split basis).
This management proposal asks shareholders to approve a 3,000,000-share increase in the authorization under Nektar’s Amended and Restated 2017 Performance Incentive Plan (after giving effect to the 1:15 reverse split). Management frames the request as necessary to preserve the company’s ability to grant stock options, RSUs and other equity-based awards to attract and retain employees and directors and to align their incentives with long‑term stockholder value, particularly as the company advances rezpegaldesleukin into Phase 3 and invests in pipeline programs. The proposal is routine in form for biotech companies but is consequential given the company’s recent positive clinical readouts and significant financing activity in 2025–2026 that increase hiring, retention needs and dilution sensitivity. The board recommends a vote “FOR,” arguing that without additional shares the company’s ability to provide competitive equity compensation would be constrained and could impair recruitment and retention at a critical development milestone. Key plan features described include anti‑repricing protections (no repricing without shareholder approval), limits on per-person annual awards, full-value award counting at a 1.5x rate, performance‑based award flexibility, change‑in‑control treatment, and a termination date for new grants (March 27, 2027) absent earlier board action. The company discloses that all directors and executive officers are eligible for awards and thus have a personal interest in approval, and quantifies current outstanding awards and available shares as of the record date. For an analyst evaluating the proposal, important considerations include the size of the requested increase relative to existing headroom and expected hiring/grant needs for planned Phase 3 programs, the mechanics for counting full‑value awards (1.5x), governance protections (no repricing without shareholder approval), and potential dilution calculations tied to market capitalization. Overall, the proposal is typical of late‑stage development biotech companies scaling clinical development and hiring, and the board’s rationale centers on operational needs to sustain development momentum and retain talent; investors will weigh the benefit of incentivizing management and staff against incremental dilution and should assess the company’s historical burn of plan shares and the tightness of current share reserves.
To ratify the Audit Committee’s selection of Ernst & Young LLP as Nektar’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
A non-binding advisory vote to approve the compensation paid to the company’s named executive officers as disclosed in the proxy statement (a 'say-on-pay' vote).
This management-sponsored advisory proposal asks shareholders to endorse (on a non‑binding basis) the Company’s executive compensation program for named executive officers as disclosed in the proxy. Management frames the program around pay‑for‑performance principles, a mix of base salary, annual cash incentives tied to corporate and individual goals, and long‑term equity (time‑based and performance‑based RSUs and options) to align management with long‑term shareholder value. The proxy highlights significant 2025 milestones—positive Phase 2b results for rezpegaldesleukin, FDA Fast Track designations, initiation/preparation for Phase 3, and strengthened cash position—and ties compensation outcomes (annual bonuses and performance awards) to those achievements. The board recommends a “FOR” vote and commits to consider the advisory outcome when making future compensation decisions; it also discloses robust governance practices (independent compensation committee, independent consultant, clawback policy, anti‑hedging, stock ownership guidelines). For a sophisticated evaluator, key issues include (i) whether incentive targets and performance metrics are sufficiently rigorous and disclosed to assess stretch versus formulaic goals, (ii) the mix of time‑based versus performance‑based equity and the historical vesting outcomes (including canceled or unmet TSR‑based awards), (iii) pay outcomes relative to realized company performance and TSR, and (iv) any potential conflicts or departures from best practices (the company discloses standard protections such as no repricing without shareholder approval and clawbacks). Given the non‑binding nature of the vote, its principal utility is as feedback to the Organization and Compensation Committee; investors should review the detailed CD&A, peer benchmarking, and realized pay-versus-performance reconciliation presented in the proxy to form a view on whether the disclosed program and outcomes warrant endorsement.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BVF INC/IL | 7.58% | 2,559,595 | $184M |
| 2 | FMR LLC | 7.23% | 2,441,314 | $176M |
| 3 | Two Seas Capital LP | 5.80% | 1,959,178 | $141M |
| 4 | FMR LLC | 5.51% | 1,861,842 | $134M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.54% | 1,197,055 | $86M |
| 6 | TWO SIGMA INVESTMENTS, LP | 2.75% | 930,741 | $67M |
| 7 | Prosight Management, LP | 2.18% | 735,000 | $53M |
| 8 | ARMISTICE CAPITAL, LLC | 1.71% | 578,000 | $42M |
| 9 | Sofinnova Investments, Inc. | 1.51% | 509,546 | $37M |
| 10 | BlackRock, Inc. | 1.39% | 470,456 | $34M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.